Last Updated: May 12, 2026

Aurobindo Pharma Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for AUROBINDO PHARMA

AUROBINDO PHARMA has five hundred and forty-nine approved drugs.

There are twenty-three tentative approvals on AUROBINDO PHARMA drugs.

Summary for Aurobindo Pharma
US Patents:0
Tradenames:414
Ingredients:386
NDAs:549
Patent Litigation for Aurobindo Pharma: See patent lawsuits for Aurobindo Pharma
PTAB Cases with Aurobindo Pharma as petitioner: See PTAB cases with Aurobindo Pharma as petitioner

Drugs and US Patents for Aurobindo Pharma

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma Ltd CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE cetirizine hydrochloride; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 212409-001 Mar 8, 2023 DISCN No No ⤷  Start Trial ⤷  Start Trial
Aurobindo Pharma Ltd NORTRIPTYLINE HYDROCHLORIDE nortriptyline hydrochloride CAPSULE;ORAL 074835-001 Jun 30, 1997 DISCN No No ⤷  Start Trial ⤷  Start Trial
Aurobindo Pharma Usa NEFAZODONE HYDROCHLORIDE nefazodone hydrochloride TABLET;ORAL 076129-003 Sep 16, 2003 DISCN No No ⤷  Start Trial ⤷  Start Trial
Aurobindo Pharma Ltd FEBUXOSTAT febuxostat TABLET;ORAL 210741-001 Oct 25, 2023 AB RX No No ⤷  Start Trial ⤷  Start Trial
Aurobindo Pharma Ltd BUSPIRONE HYDROCHLORIDE buspirone hydrochloride TABLET;ORAL 078246-005 Feb 21, 2020 AB RX No No ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Expired US Patents for Aurobindo Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Aurobindo Pharma Usa MAXZIDE-25 hydrochlorothiazide; triamterene TABLET;ORAL 019129-003 May 13, 1988 4,444,769 ⤷  Start Trial
Aurobindo Pharma Usa MAXZIDE hydrochlorothiazide; triamterene TABLET;ORAL 019129-001 Oct 22, 1984 4,105,783 ⤷  Start Trial
Aurobindo Pharma Usa MAXZIDE hydrochlorothiazide; triamterene TABLET;ORAL 019129-001 Oct 22, 1984 4,444,769 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Subscribe to access the full database, or Start Trial

Paragraph IV (Patent) Challenges for AUROBINDO PHARMA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Injection 200 mcg/vial ➤ Subscribe 2015-05-01
➤ Subscribe for Injection 100 mcg/vial and 500 mcg/vial ➤ Subscribe 2015-04-14
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links